Helixgate https://validator.w3.org/feed/docs/rss2.html Home STAT+: Did AI really beat doctors at diagnosis? Psilocybin-Induced Brain Changes May Explain Therapeutic Effects Intercept’s next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharma Pfizer’s Albert Bourla says he has no mega-merger plans STAT+: Pharma’s reputation among patient groups rose last year, but concerns remain over access and pricing STAT+: A new attack on AMA’s billing codes BioNTech to scale down manufacturing, over 1,800 jobs on the line Viridian data lift prospects for thyroid eye disease drug Pfizer is a 2029 story but Q126 lays foundation for growth Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech’s $83M After Arcellx buyout close, Gilead trims 108 jobs at CAR-T biotech’s Redwood City outpost Swiss manufacturing, biotech industry so far unfazed by geopolitics STAT+: Are analysts too quick to gloss over Lilly’s liver case? BioNTech moves to close multiple manufacturing plants, affecting 1,860 jobs QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS Madrigal extends MASH deal streak with Arrowhead drug that J&J didn’t want STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more Vertex earnings get muted investor response Vertex’s quiet Q1 is calm before potentially ‘iconic’ renal evolution Foundayo’s liver failure blip weighs down Lilly shares. but analysts unconcerned New Human-Computer Interaction Software Designed to Support Diverse Online Teamwork Styles What you need to know about hantavirus (don’t panic) FDA uncertainty persists as search for Prasad successor at CBER drags on Cytokinetics succeeds where Bristol Myers failed in heart muscle disease Genomics and Greywolf partner on autoimmune disease treatments  STAT+: Top lawmaker takes aim at doctor lobby, linking AMA’s billing codes to fraud fight IPF draws investor heat as biotechs target fibrosis halt, better tolerability Cytospire hauls in $83M for a new type of T cell engager STAT+: Johnson & Johnson advances IBD therapy, despite trial miss Sertraline manufacturer recalls antidepressant batch after UK packaging mix-up Vertex drops mRNA cystic fibrosis program over ‘tolerability’ issues Gene Syntax Determines DNA Supercoiling and Modulates Gene Expression Blood Stem Cells Evade Immune Attack in Aplastic Anemia Through Gene Mutations Protein Biomarkers in Practice: Strategies to Reduce Drug Development Risk TRACS Enables Strain-Level Tracking of Microbial Transmission STAT+: French regulator fines Novo and Lilly over weight loss ad campaigns Optical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells Opinion: Mifepristone court ruling makes drug development riskier for everyone FDA search for new CBER head focused on small group of final candidates Celcuity strengthens case for ASCO-spotlighted breast cancer drug Passage cuts 75% of workforce after FDA trial design request Supreme Court restores access to abortion pill mifepristone through telehealth, mail, and pharmacies Celcuity breast cancer win; Odyssey plans $205M IPO; Latus Bio extends Series A STAT+: Pump the brakes on AI, buddy; and deposition deadlock Big Tech Targets Drug Discovery with Wave of Life Science Platforms Federal court blocks mailing of mifepristone Gene therapy’s evidence problem—lessons from recent FDA decisions Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trial Passage launches strategic review and 75% layoffs after gene therapy path blocked by FDA